NewsBenzingaTeva Pharmaceutical Industries aumenta la guidance dell’EPS rettificato per l’esercizio 2026 da 1,91-2,11 dollari a 1,92-2,11 dollari, contro una stima di 1,98 dollari; aumenta la guidance delle vendite per l’esercizio 2026 da 16,500 miliardi di... Teva Pharmaceutical Industries aumenta la guidance dell’EPS rettificato per l’esercizio 2026 da 1,91-2,11 dollari a 1,92-2,11 dollari, contro una stima di 1,98 dollari; aumenta la guidance delle vendite per l’esercizio 2026 da 16,500 miliardi di... Benzinga 2026.11.03 12:08 (GMT+0) Open on Benzinga Other news CalPERS Discloses $37.1 Million Stake in Strategy Scammers Used Musk Deepfake Video to Defraud; Coinbase AI System Blocked $4.7 Million JPMorgan Is Developing AI Agent Trading Without Human Involvement Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense
Coinbase CEO: AI Agents to Account for Well Over 99.9% of Trading Volume Within a Decade; Bitcoin May Have Bottomed This Cycle
Jito CEO: Crypto Developers Should Slow Down in the Next Two Years and Focus on Fixing Security Flaws
Glassnode: Bitcoin Sell-Off Nears Historical Local Bottom Levels, $62,000 Becomes Key Line of Defense